BioCentury
ARTICLE | Company News

Kalidex debuts

September 5, 2012 1:14 AM UTC

Kalidex Pharmaceuticals Inc. (Menlo Park, Calif.) made its public debut on Tuesday and said it raised $45 million in a series A round in February 2011. Frazier Healthcare Ventures; Domain Associates; Canaan Partners; New Leaf Venture Partners; MPM Capital; and OrbiMed participated. Kalidex's lead product is KPI-10, a broad-spectrum fluoroquinolone antibiotic with activity against drug-resistant Gram-negative and Gram-positive bacteria. The product is in Phase I testing, with Phase II studies expected to start mid-2013. ...